Cue Biopharma (CUE) Enterprise Value (2017 - 2025)
Cue Biopharma (CUE) has disclosed Enterprise Value for 9 consecutive years, with -$27.7 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 18.41% to -$27.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$27.7 million through Dec 2025, down 18.41% year-over-year, with the annual reading at -$27.7 million for FY2025, 18.41% down from the prior year.
- Enterprise Value hit -$27.7 million in Q4 2025 for Cue Biopharma, down from -$18.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$14.0 million in Q1 2025 to a low of -$76.3 million in Q4 2022.
- Historically, Enterprise Value has averaged -$48.9 million across 5 years, with a median of -$53.4 million in 2021.
- Biggest five-year swings in Enterprise Value: plummeted 50.33% in 2021 and later skyrocketed 65.76% in 2025.
- Year by year, Enterprise Value stood at -$52.2 million in 2021, then crashed by 46.12% to -$76.3 million in 2022, then surged by 36.03% to -$48.8 million in 2023, then surged by 52.07% to -$23.4 million in 2024, then decreased by 18.41% to -$27.7 million in 2025.
- Business Quant data shows Enterprise Value for CUE at -$27.7 million in Q4 2025, -$18.2 million in Q3 2025, and -$28.0 million in Q2 2025.